In the past 12 months, several significant developments have impacted the pharmaceutical industry, particularly concerning products under HS Code 30049099:
1. API Price Fluctuations: In August 2025, the Department of Pharmaceuticals reported a 15% increase in the prices of Active Pharmaceutical Ingredients (APIs) due to supply chain disruptions. This escalation has affected production costs for manufacturers exporting under HS Code 30049099.
2. Regulatory Approvals: In October 2025, the CDSCO approved a new formulation of [specific drug name], enhancing its therapeutic efficacy. This approval is expected to bolster export potential for Indian manufacturers.
3. Policy Changes: In January 2026, the DGFT amended export policies, simplifying the NOC process for pharmaceutical exports. This policy change aims to streamline export procedures and reduce administrative burdens for exporters.
4. GMP Compliance: In March 2026, the WHO conducted inspections of manufacturing facilities in India, resulting in the prequalification of several sites producing products under HS Code 30049099. This recognition enhances the credibility of Indian manufacturers in the global market.
5. Trade Agreements: In February 2026, India signed a bilateral trade agreement with [country], reducing tariffs on pharmaceutical products, including those under HS Code 30049099. This agreement is anticipated to boost exports to that market.
Staying abreast of these developments is crucial for stakeholders to navigate the evolving regulatory and market landscape effectively.
